TICKERNOMICS Sign up
Last Update: 2023-10-04 11:32:47
Myovant Sciences Ltd. ( MYOV ) https://myovant.com
26.98USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United Kingdom
1y
3y
5y
10y
Historical Returns*:
SPY
14.73%
MYOV
5.89%
SPY
36.71%
MYOV
92.71%
SPY
70.96%
MYOV
18.02%
SPY
262.36%
MYOV
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
2613.26
2708.41
2.21
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-14.22
6.89
-4.68
-10.37
0.00
-13.27
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-51.78
65.85
-50.90
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.1585
-104.20
-84.21
1.35
Other Earnings and Cash Flow Stats:
Myovant Sciences Ltd. ( MYOV ) Net Income TTM ($MM) is -201.60
Myovant Sciences Ltd. ( MYOV ) Operating Income TTM ($MM) is -172.93
Myovant Sciences Ltd. ( MYOV ) Owners' Earnings Annual ($MM) is 0.00
Myovant Sciences Ltd. ( MYOV ) Current Price to Owners' Earnings ratio is 0.00
Myovant Sciences Ltd. ( MYOV ) EBITDA TTM ($MM) is -169.72
Myovant Sciences Ltd. ( MYOV ) EBITDA Margin is -50.90%
Capital Allocation:
Myovant Sciences Ltd. ( MYOV ) has paid 0.00 dividends per share and bought back -0.647918 million shares in the past 12 months
Myovant Sciences Ltd. ( MYOV ) has increased its debt by 0.34999999999997 million USD in the last 12 months
Capital Structure:
Myovant Sciences Ltd. ( MYOV ) Interest-bearing Debt ($MM) as of last quarter is 369
Myovant Sciences Ltd. ( MYOV ) Annual Working Capital Investments ($MM) are 35
Myovant Sciences Ltd. ( MYOV ) Book Value ($MM) as of last quarter is -559
Myovant Sciences Ltd. ( MYOV ) Debt/Capital as of last quarter is -67%
Other Balance Sheet Stats:
Myovant Sciences Ltd. ( MYOV ) has 250 million in cash on hand as of last quarter
Myovant Sciences Ltd. ( MYOV ) has 245 million of liabilities due within 12 months, and long term debt 367 as of last quarter
Myovant Sciences Ltd. ( MYOV ) has 96 common shares outstanding as of last quarter
Myovant Sciences Ltd. ( MYOV ) has 0 million USD of preferred stock value
Academic Scores:
Myovant Sciences Ltd. ( MYOV ) Altman Z-Score is -3.43 as of last quarter
Myovant Sciences Ltd. ( MYOV ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Myovant Sciences Ltd. ( MYOV ) largest shareholder is Rafferty Asset Management, LLC owning 276787 shares at 7.47 ($MM) value
Chemical Co. Ltd. Sumitomo(an insider) Bought 51599200 shares of Myovant Sciences Ltd. ( MYOV ) for the amount of $1393178400.00 on 2023-03-10
48.61% of Myovant Sciences Ltd. ( MYOV ) is held by insiders, and 56.21% is held by institutions
Myovant Sciences Ltd. ( MYOV ) went public on 2016-10-27
Other Myovant Sciences Ltd. ( MYOV ) financial metrics:
FCF:-371.69
Unlevered Free Cash Flow:-163.06
EPS:-2.40
Operating Margin:-51.78
Gross Profit Margin:65.85
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:41.30
Beta:1.35
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Myovant Sciences Ltd. ( MYOV ) :
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.